Gaithersburg, Maryland , USA
April 18, 2017 – April 19, 2017
|Registration: Click Here||Nearby Hotels: Click here||Travel Award: Click Here|
The field of immunotoxicology is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and toxicology, the need for continued training and interdisciplinary interactions are critical for those who work within this field. This is essential both for those with an immunology background who seek to apply this expertise to drug development and safety, as well as those who wish to enhance their current drug safety expertise with a deeper understanding of immunology.
How is this Training Different? Most current CE courses and other training opportunities either provide a foundation on an immunological topic or focus on a specific therapeutic area without in-depth coverage of the relevant foundational science elements or the applied drug development/drug safety context. The proposed training will expand upon other courses by including:
- – In-depth review of immunological elements critical to the key focal area for the session;
- – Contemporary and emerging immunotoxicological research trends, methods, and uncertainties in this topical area;
- – The application of these elements in the context of drug development and safety (from both a procedural and regulatory perspective); and
- – Case studies that will allow participants to apply these concepts in an interactive and educational format.
With a group of instructors that span regulatory, drug development scientists, clinicians, and academics that are experts in their field of study
- – Review the current state of the science to provide an immunological foundation that is pertinent to the course topic
- – Enhance awareness to new discoveries and the potential impact on drug development and safety
- – Provide a training mechanism that incorporates the latest science into preexisting drug development methodologies
DAY 1/Foundational Immunology: Basic T-cell Immunology and Immunopharmacology
- – T-lymphocytes Ontogeny: Yuka Kanno, NIH, NIAMS
- – T-lymphocytes Activation/Inhibition Pathways: Lawrence Kane, University of Pittsburg
- – T-cells Across Toxicology Species: Patrick J. Haley, Incyte
- – T-cell Therapies: Rod Prell, Genentech
DAY 2/Immunotoxicology and Immunopathology Associated with Therapies Affecting T-cells; Application to Drug Development
- – Integrating immunopathology and immunotoxicology data; perspectives from a toxicologic pathologist: Tracey Papenfuss, Charles River Laboratories
- – Cytokine Release Syndrome, SIRS: Richard Stebbings, Medimmune
- – Autoimmunity, AE’s with CPI’s: Isabella Glitza Oliva, MD Anderson
- – Immune-mediated Neurotoxicity: Rafael Ponce, Juno Therapeutics
- – Immunosuppression/Modulation:
- – Viral Recrudescence: Gary Burleson, Burleson Research Technology
- – Carcinogenicity Risk: Herve Lebrec, Amgen
- – Vaccination: Morgan Monslow, Merck
- – Regulatory Challenges for Immunomodulators – Emily Wearne, US FDA
Space is limited, and registration will be on a first-come, first-served basis. To register click here.
HESI Future Leaders Travel Award (FLT)
This event is eligible for the FLT Award. Read more about the award and complete the application here. Applications are due February 21, 2017.
Click here to find a list of nearby hotels. Please note that participants are responsible for their own transportation to and from Medimmune.
For additional information, please contact Mr. Oscar Bermudez (firstname.lastname@example.org).